Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 1/2022

19.08.2021 | Review Article

Systemic Therapy in Thyroid Cancer

verfasst von: Amit Kumar Agrawal, Vanita Noronha, Vijay Patil, Nandini Menon, Akhil Kapoor, Anuradha Chougule, Pratik Chandrani, Kumar Prabhash

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Thyroid cancer is the most common endocrine malignancy. While surgery remains the mainstay of the treatment of all different histologies, for differentiated thyroid cancers, radioactive iodine also plays an important role in management. Once tumor becomes radio-iodine refractory, it needs systemic therapy. Earlier, these tumors had very dismal prognosis. However, with the advancement of technology and research, it has become clear now that thyroid cancer cells are driven by various mutations. Targeting these oncogenic drivers by various molecules have proven to be effective therapeutic strategy in thyroid cancer. Besides, as in other solid tumors, immunotherapy is also being evaluated in thyroid cancer. While these new therapeutic approaches have revolutionized the treatment on advanced/metastatic thyroid cancer, there are definite challenges which limit their use in common clinical practice. These challenges include higher treatment cost and lack of testing to identify the driver mutations. Moreover, there is still need for further research in thyroid cancers to identify oncogenic targets and agent to act upon them.
Literatur
1.
Zurück zum Zitat Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, Maddalena F, Landriscina M (2019) Braf inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives. Cancers 11(9):1388PubMedCentralCrossRef Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, Maddalena F, Landriscina M (2019) Braf inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives. Cancers 11(9):1388PubMedCentralCrossRef
2.
Zurück zum Zitat DeGroot LJ, Larsen PR, Hennemann G (1996) The thyroid and its diseases. WB Saunders Company, Philadelphia DeGroot LJ, Larsen PR, Hennemann G (1996) The thyroid and its diseases. WB Saunders Company, Philadelphia
3.
Zurück zum Zitat Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306PubMedCrossRef Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306PubMedCrossRef
4.
Zurück zum Zitat DeLellis RA (ed) (2004) Pathology and genetics of tumours of endocrine organs. IARC, Lyon DeLellis RA (ed) (2004) Pathology and genetics of tumours of endocrine organs. IARC, Lyon
5.
Zurück zum Zitat Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ (1999) [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84(7):2291–2302PubMedCrossRef Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ (1999) [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84(7):2291–2302PubMedCrossRef
6.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–33PubMedPubMedCentralCrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–33PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F (2014) Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2(5):356–358PubMedCrossRef Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F (2014) Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2(5):356–358PubMedCrossRef
8.
Zurück zum Zitat Taccaliti A, Silvetti F, Palmonella G, Boscaro M (2011) Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics 12(8):618–625CrossRef Taccaliti A, Silvetti F, Palmonella G, Boscaro M (2011) Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics 12(8):618–625CrossRef
9.
Zurück zum Zitat Wells SA Jr, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon JR (1982) The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 195(5):595PubMedPubMedCentralCrossRef Wells SA Jr, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon JR (1982) The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 195(5):595PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V (2002) Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87(8):3947–3952PubMed Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V (2002) Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87(8):3947–3952PubMed
11.
12.
13.
Zurück zum Zitat Tallini G, Asa SL, Fuller GN (2001) RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8(6):345–354PubMedCrossRef Tallini G, Asa SL, Fuller GN (2001) RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8(6):345–354PubMedCrossRef
14.
Zurück zum Zitat Prasongsook N (2019) Current and future directions for the treatment of advanced thyroid cancer. Annals of Oncology. 30:vi70CrossRef Prasongsook N (2019) Current and future directions for the treatment of advanced thyroid cancer. Annals of Oncology. 30:vi70CrossRef
15.
Zurück zum Zitat Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, KeeShong Y, Sherman SI (2014) Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 384(9940):319PubMedPubMedCentralCrossRef Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, KeeShong Y, Sherman SI (2014) Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 384(9940):319PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630PubMedCrossRef Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630PubMedCrossRef
17.
Zurück zum Zitat Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134PubMedCrossRef Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134PubMedCrossRef
18.
Zurück zum Zitat Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639PubMedPubMedCentralCrossRef Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Brose MS, Robinson B, Bermingham C, Puvvada S, Borgman AE, Krzyzanowska MK, Capdevila J, Sherman SI (2019) A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy. J Clin Oncol 37:15_suppl, TPS6097-TPS6097 Brose MS, Robinson B, Bermingham C, Puvvada S, Borgman AE, Krzyzanowska MK, Capdevila J, Sherman SI (2019) A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy. J Clin Oncol 37:15_suppl, TPS6097-TPS6097
20.
Zurück zum Zitat Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S (2014) Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 120(17):2694–2703PubMedCrossRef Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S (2014) Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 120(17):2694–2703PubMedCrossRef
21.
Zurück zum Zitat Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31–42PubMedCrossRef Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31–42PubMedCrossRef
22.
Zurück zum Zitat Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794–3801PubMedCrossRef Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794–3801PubMedCrossRef
23.
Zurück zum Zitat Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C (2017) A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 76:110–117PubMedCrossRef Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C (2017) A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 76:110–117PubMedCrossRef
24.
Zurück zum Zitat Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC III, McIver B (2014) A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99(5):1687–1693PubMedPubMedCentralCrossRef Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC III, McIver B (2014) A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99(5):1687–1693PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ (2016) Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9):1272–1282PubMedPubMedCentralCrossRef Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ (2016) Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9):1272–1282PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V (2015) BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71–77PubMedPubMedCentralCrossRef Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V (2015) BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71–77PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JH, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 36(1):7PubMedCrossRef Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JH, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 36(1):7PubMedCrossRef
28.
Zurück zum Zitat Schneider TC, De Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, van Wezel T, Van Eijk R, Morreau H, Guchelaar HJ, Kapiteijn E (2015) Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial. Int J Endocrinol 1:2015 Schneider TC, De Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, van Wezel T, Van Eijk R, Morreau H, Guchelaar HJ, Kapiteijn E (2015) Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial. Int J Endocrinol 1:2015
29.
Zurück zum Zitat Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368(7):623–632PubMedPubMedCentralCrossRef Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368(7):623–632PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Ho A, Dedecjus M, Wirth LJ, Tuttle R, Tennaval J, So K, Carroll D, Hovey T, Thakre B, Fagin J (2018) ASTRA: a phase III, randomized, placebo-controlled study evaluating complete remission rate (CRR) with short-course selumetinib plus adjuvant radioactive iodine (RAI) in patients (pts) with differentiated thyroid cancer (DTC). Thyroid 3(28):A171–A172 Ho A, Dedecjus M, Wirth LJ, Tuttle R, Tennaval J, So K, Carroll D, Hovey T, Thakre B, Fagin J (2018) ASTRA: a phase III, randomized, placebo-controlled study evaluating complete remission rate (CRR) with short-course selumetinib plus adjuvant radioactive iodine (RAI) in patients (pts) with differentiated thyroid cancer (DTC). Thyroid 3(28):A171–A172
31.
Zurück zum Zitat Shah MH, Sherman EJ, Robinson B, Solomon BJ, Kang H, Lorch JH, Worden FP, Brose MS, Leboulleux S, Godbert Y, Meurer M (2020) Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer. J Clin Oncol 38:15_suppl, 3594-3594 Shah MH, Sherman EJ, Robinson B, Solomon BJ, Kang H, Lorch JH, Worden FP, Brose MS, Leboulleux S, Godbert Y, Meurer M (2020) Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer. J Clin Oncol 38:15_suppl, 3594-3594
32.
Zurück zum Zitat Subbiah V, Taylor M, Lin J, Hu M, Ou S, Brose M, Garralda E, Clifford C, Palmer M, Tugnait M, Evans E (2018) Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors. In: Proceedings of the american association for cancer research annual meeting (pp. 14–18) Subbiah V, Taylor M, Lin J, Hu M, Ou S, Brose M, Garralda E, Clifford C, Palmer M, Tugnait M, Evans E (2018) Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors. In: Proceedings of the american association for cancer research annual meeting (pp. 14–18)
33.
Zurück zum Zitat Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A (2013) Sorafenib and thyroid cancer. BioDrugs 27(6):615–628PubMedCrossRef Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A (2013) Sorafenib and thyroid cancer. BioDrugs 27(6):615–628PubMedCrossRef
34.
Zurück zum Zitat Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165(2):315PubMedCrossRef Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165(2):315PubMedCrossRef
35.
Zurück zum Zitat Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, Brose MS (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26(29):4714PubMedPubMedCentralCrossRef Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, Brose MS (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26(29):4714PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323PubMedPubMedCentralCrossRef Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Guo T, Liu P, Yang J, Wu P, Chen B, Liu Z, Li Z (2019) Evaluation of targeted agents for advanced and unresectable hepatocellular carcinoma: a network meta-analysis. J Cancer 10(19):4671PubMedPubMedCentralCrossRef Guo T, Liu P, Yang J, Wu P, Chen B, Liu Z, Li Z (2019) Evaluation of targeted agents for advanced and unresectable hepatocellular carcinoma: a network meta-analysis. J Cancer 10(19):4671PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16):2749–2756PubMedCrossRef Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16):2749–2756PubMedCrossRef
39.
Zurück zum Zitat Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, Infanger M, Wehland M (2018) Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int J Mol Sci 19(10):3258PubMedCentralCrossRef Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, Infanger M, Wehland M (2018) Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int J Mol Sci 19(10):3258PubMedCentralCrossRef
40.
Zurück zum Zitat Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767PubMedPubMedCentralCrossRef Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, Antonelli A (2015) Cabozantinib in thyroid cancer. Recent Pat Anticancer Drug Discov. 10(3):259–69PubMedCrossRef Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, Antonelli A (2015) Cabozantinib in thyroid cancer. Recent Pat Anticancer Drug Discov. 10(3):259–69PubMedCrossRef
42.
Zurück zum Zitat Brose MS, Shenoy S, Bhat N, Harlacker AK, Yurtal RK, Posey ZA, Torrente DM, Grande C, Squillante CM, Troxel AB, Yarchoan M (2018) A phase 2 trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting. Int J Radiat Oncol Biol Phys. 100(5):1311CrossRef Brose MS, Shenoy S, Bhat N, Harlacker AK, Yurtal RK, Posey ZA, Torrente DM, Grande C, Squillante CM, Troxel AB, Yarchoan M (2018) A phase 2 trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting. Int J Radiat Oncol Biol Phys. 100(5):1311CrossRef
43.
Zurück zum Zitat Capdevila J, Trigo JM, Aller J, Manzano JL, Adrián SG, Llopis CZ, Reig Ò, Bohn U, y Cajal TR, Duran-Poveda M, Astorga BG (2017) Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur J Endocrinol. 177(4):309–17PubMedCrossRef Capdevila J, Trigo JM, Aller J, Manzano JL, Adrián SG, Llopis CZ, Reig Ò, Bohn U, y Cajal TR, Duran-Poveda M, Astorga BG (2017) Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur J Endocrinol. 177(4):309–17PubMedCrossRef
44.
Zurück zum Zitat Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, Ragusa F, Antonelli A, Fallahi P (2019) Sunitinib in the treatment of thyroid cancer. Curr Med Chem 26(6):963–972PubMedCrossRef Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, Ragusa F, Antonelli A, Fallahi P (2019) Sunitinib in the treatment of thyroid cancer. Curr Med Chem 26(6):963–972PubMedCrossRef
45.
Zurück zum Zitat Espinosa AV, Porchia L, Ringel MD (2007) Targeting BRAF in thyroid cancer. Br J Cancer 96(1):16–20PubMedCrossRef Espinosa AV, Porchia L, Ringel MD (2007) Targeting BRAF in thyroid cancer. Br J Cancer 96(1):16–20PubMedCrossRef
46.
47.
Zurück zum Zitat Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92(7):2840–2843PubMedCrossRef Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92(7):2840–2843PubMedCrossRef
48.
Zurück zum Zitat Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S (2019) Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J Clin Endocrinol Metab 104(5):1417–1428PubMedCrossRef Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S (2019) Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J Clin Endocrinol Metab 104(5):1417–1428PubMedCrossRef
49.
Zurück zum Zitat Eroglu Z, Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 8(1):48–56PubMedPubMedCentralCrossRef Eroglu Z, Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 8(1):48–56PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Shah MH, Wei L, Wirth LJ, Daniels GA, De Souza JA, Timmers CD, Sexton JL, Beshara M, Nichols D, Snyder N, Devine CE (2017) Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol 35:15_suppl, 6022-6022 Shah MH, Wei L, Wirth LJ, Daniels GA, De Souza JA, Timmers CD, Sexton JL, Beshara M, Nichols D, Snyder N, Devine CE (2017) Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol 35:15_suppl, 6022-6022
51.
Zurück zum Zitat Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036–1043PubMedPubMedCentralCrossRef Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036–1043PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Drilon AE, Subbiah V, Oxnard GR, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME, Johnson ML (2018) A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol 36:15_suppl, 102-102 Drilon AE, Subbiah V, Oxnard GR, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME, Johnson ML (2018) A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol 36:15_suppl, 102-102
53.
Zurück zum Zitat Liu J, Liu Y, Lin Y, Liang J (2019) Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol Metab 34(3):215CrossRef Liu J, Liu Y, Lin Y, Liang J (2019) Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol Metab 34(3):215CrossRef
54.
Zurück zum Zitat Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ (2015) Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 21(5):1028–1035PubMedCrossRef Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ (2015) Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 21(5):1028–1035PubMedCrossRef
55.
Zurück zum Zitat Albero A, Lopéz JE, Torres A, de la Cruz L, Martín T (2016) Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr Relat Cancer 23(2):R71-84PubMedCrossRef Albero A, Lopéz JE, Torres A, de la Cruz L, Martín T (2016) Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr Relat Cancer 23(2):R71-84PubMedCrossRef
56.
Zurück zum Zitat Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104–1139PubMedCrossRef Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104–1139PubMedCrossRef
57.
Zurück zum Zitat Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60(10):2372–2375PubMedCrossRef Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60(10):2372–2375PubMedCrossRef
58.
Zurück zum Zitat Wendler J, Kroiss M, Gast K, Kreissl M, Allelein S, Lichtenauer U, Blaser R, Kuhn K, Spitzweg C, Fassnacht M, Fuhrer D (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma in Germany: a retrospective multi-center study. In18th European Congress of Endocrinology (Vol. 41). BioScientifica Wendler J, Kroiss M, Gast K, Kreissl M, Allelein S, Lichtenauer U, Blaser R, Kuhn K, Spitzweg C, Fassnacht M, Fuhrer D (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma in Germany: a retrospective multi-center study. In18th European Congress of Endocrinology (Vol. 41). BioScientifica
59.
Zurück zum Zitat Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito KI, Yoshida A, Suganuma N, Nakashima N, Suzuki S, Tsukahara K (2016) The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 26(9):1293–1299PubMedCrossRef Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito KI, Yoshida A, Suganuma N, Nakashima N, Suzuki S, Tsukahara K (2016) The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 26(9):1293–1299PubMedCrossRef
60.
Zurück zum Zitat Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR (2014) Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 24(2):232–240PubMedCrossRef Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR (2014) Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 24(2):232–240PubMedCrossRef
61.
Zurück zum Zitat French JD (2020) Immunotherapy for advanced thyroid cancers—rationale, current advances and future strategies. Nat Rev Endocrinol 16(11):629–641PubMedCrossRef French JD (2020) Immunotherapy for advanced thyroid cancers—rationale, current advances and future strategies. Nat Rev Endocrinol 16(11):629–641PubMedCrossRef
62.
Zurück zum Zitat Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24(2):97–106PubMedCrossRef Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24(2):97–106PubMedCrossRef
64.
Zurück zum Zitat Mehnert JM, Varga A, Brose M, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J (2016) Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol 34:15_suppl, 6091-6091 Mehnert JM, Varga A, Brose M, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J (2016) Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol 34:15_suppl, 6091-6091
66.
Zurück zum Zitat Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD (2018) Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):1CrossRef Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD (2018) Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):1CrossRef
67.
Zurück zum Zitat Dierks C, Seufert J, Ruf J, Duyster J, Thomusch O, Miething C, Zielke A (2020) 1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: results from a retrospective study and first results from the prospective phase II ATLEP trial. Ann Oncol 1(31):S1085CrossRef Dierks C, Seufert J, Ruf J, Duyster J, Thomusch O, Miething C, Zielke A (2020) 1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: results from a retrospective study and first results from the prospective phase II ATLEP trial. Ann Oncol 1(31):S1085CrossRef
68.
Zurück zum Zitat Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ (2019) A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid 29(11):1615–1622PubMedCrossRef Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ (2019) A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid 29(11):1615–1622PubMedCrossRef
69.
Zurück zum Zitat Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25(13):3753–3758PubMedCrossRef Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25(13):3753–3758PubMedCrossRef
71.
Zurück zum Zitat Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21(4):531–540PubMedPubMedCentralCrossRef Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21(4):531–540PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21(2):271–282PubMedCrossRef Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21(2):271–282PubMedCrossRef
Metadaten
Titel
Systemic Therapy in Thyroid Cancer
verfasst von
Amit Kumar Agrawal
Vanita Noronha
Vijay Patil
Nandini Menon
Akhil Kapoor
Anuradha Chougule
Pratik Chandrani
Kumar Prabhash
Publikationsdatum
19.08.2021
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 1/2022
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-021-01398-2

Weitere Artikel der Ausgabe 1/2022

Indian Journal of Surgical Oncology 1/2022 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.